Regeneron Shares CRATER After Fianlimab Can't “Get It Up” To Significance
Close but no cigar…
Well friends, Regeneron's experimental melanoma drug spent the weekend doing the one thing a cancer drug is hired to do, keeping patients alive longer than the competition… and yet, got rewarded with a Monday morning guillotine of -11.8%. Tough crowd.
The drug is fianlimab, and pairing it with Regeneron's already-approved Libtayo was supposed to be the company's defining moment of 2026. Instead, the late-stage trial missed its primary endpoint. It did not improve progression-free survival, the measure of how long patients live before their advanced melanoma worsens, by a statistically significant margin over Merck's Keytruda. That said, the fianlimab combo did beat Keytruda, which is precisely what makes the cheek clapping worse.
Patients on the high-dose combination went a median 11.5 months before their cancer progressed, against 6.4 months for Keytruda alone. That is roughly five extra months of life. The trial just couldn't prove, to the exacting standards of a p-value, that those five months weren't a fluke. (Five months of survival is a strange thing to file under "maybe.") In the company's own telling, the combo beat "showed a numeric improvement over" Keytruda, and in a Phase 3 readout, the quotation marks are the whole story.
Friendly reminder of how binary this stuff is. A melanoma readout is a coin flip that 1,546 patients and several years of work eventually have to land on. Heads, you reset the standard of care in first-line melanoma. Tails, you wake up Saturday to a press release and Citi tossing your salad into neutral with a price target taken from $900 to $700.
Additionally, Evercore's Cory Kasimov called the outcome "the worst-case scenario," a genuinely striking thing to say about data in which a drug extended lives. BMO's Evan Seigerman had flagged beforehand that this was "the defining catalyst of 1H26, with share sentiment inextricably tied to this release." Sentiment, right on cue, did its thing.To be fair though, and Kasimov said this part too, the fundamental damage is limited. Regeneron is not a one-drug company. Dupixent is still printing money, the Q1 numbers beat, and the company just waved through another $3 billion buyback. fianlimab was the upside lottery ticket, not the rent money. (Spoiler: Losing the lottery still stings when you've already spent the winnings in your head.)
Which brings us to the one tough pill to swallow (literally and figuratively): LAG-3, the drug class fianlimab belongs to, has a long history of humbling the companies that bet on it. The lone success story is Opdualag, Bristol Myers Squibb's LAG-3 combo. And Regeneron's next Phase 3 for fianlimab is a head-to-head against, of all the drugs on Earth, that one. Meaning, while Regeneron’s combo combo couldn't put away Keytruda monotherapy with a clean punch, the next opponent is the only fighter in the class with a friggin’ belt. Place your bets accordingly. Until next time, friends…

At the time of publishing, Stocks.News holds positions in Merck & Co. as mentioned in the article.